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Abstract  Spontaneous  methicillin-sensitive  Staphylococcus  aureus  spondylodisci-
tis  is  increasing  in  prevalence  and  there  appears  to  be  little  consensus  on  the
optimum  management  of  this  condition.  This  paper  analyses  antimicrobial  therapy
and  associated  outcomes  over  a  seven-year  period  at  a  large  UK  hospital  trust.  A
retrospective  search  strategy  identiﬁed  55  patients;  notes  were  available  for  39.
Patients  were  treated  with  a  median  12  weeks  of  antibiotics  (IQR  7),  with  6  weeks
intravenous  (IQR  3)  and  9  weeks  oral  therapy  (IQR  6).  23  different  treatment  regi-
mens  were  utilised.  33/36  (92%)  patients  for  whom  outcomes  were  available  were
cured  or  improved  at  latest  follow-up.  This  study  reports  a  wide  variation  in  antibi-
otic  prescribing  at  a  single  centre.  Outcomes  were  generally  positive  regardless
of  total  duration  of  therapy  and  proportion  of  intravenous  therapy.  These  ﬁnd-
ings  highlight  the  need  for  multi-centre  prospective  randomised  controlled  trials
to  determine  the  most  clinically  effective  and  low-risk  treatment  strategy.
©  2013  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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pontaneous  infectious  spondylodiscitis  is deﬁned
s an  infection  of  the  intervertebral  disc  space
 Sciences. Published by Elsevier Ltd. All rights reserved.
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rreatment  of  Staphylococcus  aureus  spondylodiscit
ot  resulting  from  iatrogenic  causes.  It  is  report-
dly increasing  in  incidence  [1,2]  (estimated  at
.4—2.4 per  100,000  per  year)  and  this  is  attributed
o an  ageing  population,  increasing  prevalence  of
mmunodeﬁciency  [3]  and  improved  radiological
echniques [4]. Other  risk  factors  include  dia-
etes  mellitus,  malignancy,  alcohol  dependence
yndrome, liver  cirrhosis  and  intravenous  drug  use
3].  Multiple  pathogens  have  been  implicated  but
taphylococcus  aureus  is  the  commonest  isolate
n most  series,  accounting  for  between  15  and
4% of  cases  [1,2,5].  Initial  presentation  is  usu-
lly non-speciﬁc  with  back  pain,  fever  or  anorexia
nd neurological  manifestations  occur  late.  Accord-
ngly, diagnosis  is  often  delayed  [1]  and  this
ncreases the  risk  of  complications  such  as  spinal
nstability  and  neurological  deﬁcit  [5].  Mortality  is
eported to  be  between  2  and  11%  but  if  antibi-
tics are  given  in  a  timely  fashion,  the  majority
f patients  respond  favourably  and  avoid  long-term
eurological complications  [5—7].
Although  there  have  been  a  number  of  ret-
ospective reviews  of  the  management  of  adult
pontaneous  spondylodiscitis,  there  are  currently
o published  prospective  randomised  controlled  tri-
ls [6,8—16].  Recommendations  on  antimicrobial
herapy for  spondylodiscitis  have  been  published
n France  and  the  UK  [11,17,18]. However  there
ppears to  be  little  consensus  on  antimicrobial
hoice or  duration  in  practice,  either  within  or
etween  institutions,  although  a  minimum  of  12
eeks therapy  (often  with  six  weeks  via  the
ntravenous route  followed  by  an  oral  agent)  is
ommonly  quoted  [2,5,6,11]. Furthermore,  there
s limited  research  focussing  on  infection  with
ethicillin-sensitive  S.  aureus  (MSSA)  even  though
his is a  common  aetiological  agent.  There  is  a
lear need  to  deﬁne  the  optimal  management  of
his condition  in  order  to  reduce  the  morbidity  and
ortality  associated  both  with  under-treatment
nd with  unnecessary  prolongation  of  antimicrobial
herapy. Accordingly,  this  study  aimed  to  assess  the
anagement  of  MSSA  spontaneous  spondylodiscitis
t a  UK  teaching  hospital  trust  over  a  seven-year
eriod, exploring  in  particular  what  lessons  could
e learnt  from  local  antimicrobial  prescribing  pat-
erns and  their  associated  outcomes.
aterials and methodshe  Shefﬁeld  Teaching  Hospitals  NHS  Foundation
rust is  one  of  the  largest  hospital  trusts  in  the
nited Kingdom  and  has  regional  departments  in
nfectious  diseases,  orthopaedics  and  neurosurgery.
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dult  patients  with  MSSA  spondylodiscitis  treated
etween  2005  and  2012  were  identiﬁed  through  the
ospital coding  system  and  infectious  diseases  and
icrobiology  databases.  This  highlighted  187  pos-
ible cases  and  eligibility  for  inclusion  was  further
ssessed  using  the  following  criteria:
. Spontaneous  spondylodiscitis  (deﬁned  as  non-
iatrogenic)  diagnosed  on  clinical  grounds  and
radiological investigation  (magnetic  resonance
imaging or  computed  tomography).
. MSSA  infection  identiﬁed  on  culture  of  blood  or
disc biopsy  or  both.
The  medical  notes  of  these  patients  were
eviewed, together  with  the  results  of  their
nvestigations through  the  trust’s  computerised
nvestigation  reporting  system.
Risk factors  for  spondylodiscitis  were  deﬁned
s diabetes  mellitus,  age  greater  than  60  years,
mmunosuppression  (including  current  use  of  rel-
vant medication  and  other  disease  such  as  HIV),
ctive malignancy,  alcohol  dependence  syndrome
deﬁned as  frequent  consumption  of  alcohol  in
xcess of  guidelines  with  documented  evidence  of
olerance or  withdrawal),  current  intravenous  drug
se and  liver  cirrhosis  (diagnosed  on  liver  biopsy)
18]. When  recording  antimicrobial  therapy  data,
nly antibiotic  regimes  administered  for  more  than
ve days  continuously  were  included.  Laboratory
esults (white  cell  count  (WCC),  C-reactive  protein
nd erythrocyte  sedimentation  rate  (ESR))  were
ecorded  at  diagnosis  and  at  ﬁnal  follow  up.  Out-
omes were  deﬁned  as  follows:  cured  —  no  further
pondylodiscitis  symptoms  and  no  residual  prob-
ems; relapsed  —  symptoms  improved  but  further
pisode at  a later  date;  improved  —  spondylodisci-
is symptoms  improved  but  some  residual  problems;
eath  —  due  to  spondylodiscitis  or  other  cause;  and
nknown  — lost  to  follow  up.
The project  was  approved  by  the  local  clinical
ffectiveness department.  Ethical  approval  was  not
equired.
esults
atient demographics and infection
haracteristics
e  identiﬁed  55  cases  that  met  the  inclusion  crite-
ia, however,  medical  records  were  available  for  39
atients due  to  a  local  policy  of  destroying  older
ecords or  archiving  them  in  off-site  storage.  Of
his cohort  27/39  (69%)  were  male  and  the  median
ge at  diagnosis  was  65  years  (interquartile  range
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[IQR]  22).  The  majority  of  patients  had  at  least
one co-morbidity  that  may  have  increased  their  risk
of spondylodiscitis,  most  commonly  age  (51%)  and
diabetes mellitus  (21%).  The  lumbar  spine  was  the
commonest  site  of  infection  (26  cases,  67%)  and  the
majority had  infection  at  a  single  disc  space  (69%).
MSSA was  cultured  from  either  blood  (62%),  disc
biopsy  (28%)  or  both  (10%).  Of  the  original  171  cases
of clinically  and  radiologically  conﬁrmed  sponta-
neous  spondylodiscitis,  96  had  a  positive  blood
and/or  disc  culture,  and  of  these,  MSSA  was  the
most commonly  isolated  pathogen  (55/96,  57%).
Antibiotic therapy
The  median  total  duration  of  antibiotic  therapy  was
12 weeks  (IQR  7),  with  a  median  of  6  weeks  intra-
venous (IQR  3)  and  9 weeks  oral  treatment  (IQR
6) (Fig.  1).  Eleven  patients  (28%)  received  exactly
12 weeks  of  therapy  whilst  17  (44%)  had  a longer
course and  11  (28%)  received  less.  Six  patients
had protracted  courses  (greater  than  22  weeks).
In four  cases,  antibiotics  were  prolonged  because
of progression  of  back  pain,  failure  of  inﬂamma-
tory markers  to  settle  or  on-going  pyrexia.  The
remaining two  patients  developed  new  pathology
(endocarditis and  osteomyelitis,  respectively).
All patients  received  initial  intravenous  therapy.
In ﬁve  cases  switch  to  oral  therapy  did  not  occur:
this included  two  patients  who  died  at  an  early
stage in  their  treatment  course.  A  total  of  24  dif-
ferent  antibiotic  regimes  were  used,  but  the  most
common  regimes  prescribed  at  any  point  during  the
treatment  course  were  ﬂucloxacillin  (intravenous)
with oral  fucidic  acid  (n  = 14),  and  ﬂucloxacillin
(oral) alone  (n  =  14)  (Table  1).  Reasons  for  multiple
regimes included  poor  antibiotic  response,  devel-
opment  of  concurrent  infections  and  adverse  drug
reactions.  Four  patients  had  a  penicillin  allergy  and
did not  receive  ﬂucloxacillin,  and  one  required  an
alternative  agent  due  to  worsening  liver  function
tests.
Surgical intervention
Seven  patients  (18%)  had  surgical  intervention  in
addition to  antibiotic  therapy.  Five  patients  had
spinal decompression,  one  had  spinal  stabilisation
with disc  space  debridement,  and  one  underwent
posterior thoracic  fusion.
OutcomesLength  of  follow-up  was  highly  variable,  with  a
median  of  22  weeks  (IQR  36).  Three  patients  (8%)
were lost  to  follow  up,  and  three  deaths  occurred
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mT.  Locke  et  al.
uring  antibiotic  therapy.  The  ﬁrst  was  an  82-
ear-old  male  who  died  during  intravenous  therapy
ue to  pneumonia  and  congestive  cardiac  fail-
re. The  second  was  a 70-year-old  female  who
ad developed  a MSSA  bacteraemia  and  secondary
ulti-organ failure  (intravenous  therapy  was  on
oing). The  ﬁnal  patient  was  a 67-year-old  female
ho developed  an  obstructed  tracheostomy  sec-
ndary to  a mucus  plug  and  suffered  a  cardiac
rrest (intravenous  therapy  was  complete).  The
nterval between  diagnosis  and  death  was  six,  seven
nd nine  weeks,  respectively.  Of  the  remaining  33
atients,  ten  (26%  overall)  were  reported  as  cured
nd 22  (56%  overall)  improved  at  ﬁnal  follow-up,
ith parallel  improvement  in  laboratory  markers.
ne patient  showed  improvement  after  receiving
reatment with  six  weeks  intravenous  and  then
ve weeks  oral  antibiotics.  However,  she  was  read-
itted 20  days  after  completing  treatment  with
ncreasing  back  pain,  reduced  mobility  and  pyrexia.
he clinical  impression  was  of  relapse  of  infec-
ion, supported  by  a  secondary  rise  in  inﬂammatory
arkers. However,  repeat  MRI  scan  showed  little
hange,  further  blood  cultures  were  negative  and
here was  no  evidence  of  infective  endocarditis
n echocardiography.  She  was  re-treated  with  oral
lindamycin  and  ciproﬂoxacin  and  made  a success-
ul recovery.
When  comparing  total  duration  of  treatment
intravenous  and  oral),  similar  outcomes  were
oted between  patients  receiving  ≤12  weeks  vs.
12 weeks  (82%  vs.  100%  cured  or  improved  respec-
ively, excluding  three  patients  where  outcome
nknown). Most  patients  had  a combination  of
ntravenous  then  oral  antibiotic  therapy.  Outcomes
ere similar  for  patients  treated  with  ≤4  weeks  vs.
4 weeks  intravenous  therapy  (92%  vs.  87%  cured
r improved,  respectively,  excluding  three  patients
here  outcome  unknown).
iscussion
his  study  aimed  to  explore  antibiotic  prescribing
ractice and  subsequent  outcomes  for  patients  with
SSA spondylodiscitis  at  a large  UK  hospital  trust.  A
triking feature  of  this  series  is  the  signiﬁcant  varia-
ion in  antibiotic  prescribing  within  a  single  centre.
here appears  to  be  little  standardisation  of  antibi-
tic regimes;  24  different  combinations  were  used
n 39  patients  despite  all  patients  having  conﬁrmed
SSA infection.  Furthermore,  the  total  duration
f therapy  differed  markedly  between  patients.
lthough disease  severity  and  treatment  require-
ents do  vary,  this  disparity  highlights  a  lack  of
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Fig.  1  Duration  of  intravenous  and  oral  antibiotic  therapy  for  each  patient.
Table  1  Antibiotic  regime  of  5  days  or  more  used  at  any  point  during  the  treatment  of  spontaneous  MSSA  discitis.
Drug  regime  Number  of  cases  Percentage  (1d.p)
Flucloxacillin  (IV)  +  one  other  antibiotica 23  30.3
Flucloxacillin  (PO)  only  14  18.4
Flucloxacillin  (IV)  only  13  17.1
Flucloxacillin  (PO)  +  one  other  antibioticb 10  13.2
Ciproﬂoxacin  (PO)  +  one  other  antibioticc 3  3.9
Teicoplanin  (IV)  +  one  other  antibioticd 3  3.9
Ciproﬂoxacin  (IV)  +  two  other  antibioticse 1  1.3
Clindamycin  (PO)  +  one  other  antibioticf 1  1.3
Doxycycline  (PO)  only  1  1.3
Meropenem  (IV)  only  1  1.3
Piperacillin/tazobactam  (IV)  only  1  1.3
Piperacillin/tazobactam  (IV)  + one  other  antibioticg 1  1.3
Vancomycin  (IV)  only  1  1.3
Vancomycin  (IV)  +  one  other  antibiotich 1  1.3
Vancomycin  (IV)  +  two  other  antibioticsi 1  1.3
Cefuroxime  (IV)  1  1.3
Totals  76  100
PO, oral therapy; IV, intravenous therapy.
a Fucidic acid (PO) (n = 14), rifampicin (PO) (n = 5), fucidic acid (IV) (n = 1), cefuroxime (IV) (n = 1), piperacillin/tazobactam(IV)
(n = 1), clindamycin (PO) (n = 1).
b Fucidic acid (PO) (n = 5), rifampicin (PO) (n = 5).
c Rifampicin (PO) (n = 2), doxycycline (PO) (n = 1).
d Rifampicin (PO) (n = 2), clindamycin (IV) (n = 1).
e Metronidazole (IV) with cefuroxime (IV) (n = 1).
f Rifampicin (PO) (n = 1).
g Vancomycin (IV) (n = 1).
h Rifampicin (PO) (n = 1).
i Rifampicin (PO) with cefuroxime (IV) (n = 1).
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consensus  and  echoes  ﬁndings  from  other  centres
[5,8,19].  These  observations  may  be  due  partly
to the  multi-speciality  management  of  this  con-
dition. Attempts  have  been  made  to  address  this
locally,  through  the  establishment  of  a  monthly
multidisciplinary  spinal  infection  meeting  in  August
2008, involving  clinicians  from  the  departments
of infectious  diseases,  orthopaedics,  neurosurgery,
microbiology, radiology  and  spinal  injuries.  All
patients with  spondylodiscitis  or  other  spinal  infec-
tions within  the  trust  are  discussed  and  a consensus
action plan  developed.  A  formal  review  of  the
impact of  this  service  is  awaited.
Although  recent  reviews  suggest  that  the  major-
ity of  cases  of  spondylodiscitis  are  managed  with  12
weeks antibiotic  therapy  [1,2,5], in  this  series  over
half received  either  much  longer  or  much  shorter
courses. In  spite  of  this  variability,  outcomes  were
comparable  between  these  two  groups  and  were
almost  universally  positive.  Similarly,  when  com-
paring those  receiving  predominantly  oral  therapy
compared  to  predominantly  intravenous  therapy,
outcomes were  also  generally  positive.  These  ﬁnd-
ings are  at  odds  with  other  papers  that  emphasise
the importance  of  prolonged  antimicrobial  ther-
apy in  this  condition  in  order  to  reduce  subsequent
recurrence [1,10,11,15].  Shorter  courses  with  pre-
dominantly  oral  dosing  may  help  to  minimise  the
risk of  drug  side  effects  and  facilitate  early  hospital
discharge.  However,  this  needs  to  be  cautiously  bal-
anced against  a  number  of  factors.  Firstly,  patients
are often  given  at  least  two  weeks  intravenous  ther-
apy for  S.  aureus  bacteraemia  in  order  to  minimise
complications and  reduce  mortality;  this  may  limit
the early  use  of  oral  therapy  [20,21]. Secondly,  the
length of  follow-up  needs  to  be  sufﬁcient,  in  order
to monitor  for  relapses  or  distant  spread  of  infec-
tion. The  optimum  period  remains  unclear;  Kaasch
et al.  advocate  a  follow-up  period  of  three  months
for milder  cases  based  on  the  observation  that
relapse tends  to  occur  within  two  months  and  mor-
tality remains  unchanged  after  this  period  [22,23].
In this  case  series,  follow-up  tended  to  be  much
longer than  this,  and  it  is  unlikely  therefore  that
late complications  were  missed.
The ﬁnal  number  of  cases  of  spontaneous  MSSA
spondylodiscitis  reviewed  here  is  small,  highlight-
ing the  relative  infrequency  of  this  condition  in  a
single centre,  and  limiting  the  conclusions  that  can
be drawn.  However,  to  the  authors’  knowledge  no
other such  case  series  has  been  described;  other
large retrospective  reviews  have  included  subjects
with infections  caused  by  a  range  of  pathogens,
including some  without  microbiological  conﬁrma-
tion of  infection  [4,6,13]. The  authors  acknowledge
the potential  for  bias  in  the  broad  conclusions  beingT.  Locke  et  al.
rawn.  Notably,  patients  with  less  complex  infec-
ion may  have  received  shorter  treatment  courses
ith predominantly  oral  therapy,  whilst  retaining
elatively good  outcomes.  However,  no  association
as seen  in  this  cohort  between  baseline  labora-
ory markers  and  total  duration  of  antibiotics.  The
elatively  low  incidence  of  this  condition  will  neces-
itate a multi-centre  collaboration  in  order  to  eval-
ate different  treatment  strategies  prospectively.
onclusion
SSA  spontaneous  spondylodiscitis  is  increasing  in
revalence  and  there  appears  to  be  little  consen-
us on  the  optimum  management  of  this  condition.
his report  demonstrates  a wide  variation  in  antibi-
tic therapy  in  a  single  centre,  yet  outcomes  were
enerally  positive  regardless  of  total  duration  of
herapy and  proportion  of  intravenous  therapy.
hese ﬁndings  highlight  the  need  for  multi-centre
rospective randomised  controlled  trials  to  deter-
ine the  most  clinically  effective  and  low-risk
reatment strategy.
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